67 patents
Utility
Rationally Designed, Synthetic Antibody Libraries and Uses Therefor
14 Dec 23
The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity.
Maximiliano Vasquez, Michael Feldhaus, Tillman U. Gerngross, Karl Dane Wittrup
Filed: 30 Aug 23
Utility
Rationally Designed, Synthetic Antibody Libraries and Uses Therefor
2 Nov 23
The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity.
Maximiliano Vasquez, Michael Feldhaus, Tillman U. Gerngross, K. Dane Wittrup
Filed: 1 Jul 22
Utility
Anti-respiratory Syncytial Virus Antibodies, and Methods of Their Generation and Use
28 Sep 23
Abstract: Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as nucleic acid sequences encoding such antibodies, methods for their identification, isolation, generation, and methods for their preparation and use are provided.
Laura M. WALKER
Filed: 13 Sep 22
Utility
Anti-coagulation Factor XI Antibodies
14 Sep 23
Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz, Vaishnavi Ganti, Mohammad Tabrizifard
Filed: 18 Apr 23
Utility
Antibodies against BACE1 and use thereof for neural disease immunotherapy
5 Sep 23
The invention provides antagonistic antibodies to BACE1 and methods of using the same for the treatment of neurological disease and disorders.
Yichin Liu, Jasvinder Atwal, Cecilia Pui Chi Chiu, Ryan J. Watts, Yan Wu, Eric Krauland, Michael Feldhaus
Filed: 7 Dec 20
Utility
Anti-coagulation factor XI antibodies
30 May 23
Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard, Bianka Prinz
Filed: 1 May 20
Utility
ANTI-CD3-BINDING Domains and Antibodies Comprising Them, and Methods for Their Generation and Use
18 May 23
Anti-CD3 binding domains and antibodies comprising them, including multispecific antibodies, with, inter alia, desirable T-cell activation and (re)directed target cell killing potency and developability, profiles are provided, as well as methods for their identification, isolation, and generation, and methods for their preparation and use.
Laura M. Walker, Robert Pejchal, Eric Krauland, Maximiliano Vasquez, Monica Wai Ling Leung
Filed: 11 Nov 22
Utility
Polyclonal Mixtures of Antibodies, and Methods of Making and Using Them
9 Mar 23
A method of broadening epitopic coverage of an antigen of interest, wherein a first sample of the antigen of interest is contacted with a first plurality of host cells collectively expressing a first library of antibodies.
Laura M. Walker, Eric Krauland, Karl Dane Wittrup
Filed: 13 Jun 22
Utility
ANTI-IL-27 Antibodies and Uses Thereof
9 Feb 23
The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof.
Jonathan HILL, Scott CHAPPEL, Michael GLADSTONE, Bianka PRINZ, Andrew LAKE, Christine MILLER, Kerry WHITE, Jing HUA, Pamela M. HOLLAND, Matthew RAUSCH, Devapregasan MOODLEY
Filed: 6 Apr 22
Utility
Monoclonal Antibodies and Cocktails for Treatment of Ebola Infections
9 Feb 23
Described herein are compositions and methods for the prevention and treatment of ebolavirus infection.
Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
Filed: 1 Jul 22
Utility
Anti-crimean-congo Hemorrhagic Fever Virus Antibodies, and Methods of Their Generation and Use
5 Jan 23
Anti-CCHFV antibodies with neutralizing potency and protective efficacy against CCHFV are provided, as well as methods for their identification, isolation, generation, and methods for their preparation and use are provided.
Zachary A. Bornholdt, Akaash Mishra, Laura M. Walker, Noel T. Pauli, Daniel Maurer, Kartik Chandran, Jens Maximilian Fels, Dafna Abelson, Jason Scott McLellan, Jonathan R. Lai, Ariel Wirchnianski, Olivia Vergnolle, John M. Dye, Andrew S. Herbert
Filed: 31 May 22
Utility
High Affinity ANTI-CD3 Antibodies, and Methods for Their Generation and Use
5 Jan 23
Antibodies and antigen-binding fragments thereof with high affinity for CD3 and desirable developability profiles are provided, as well as methods for their manufacture and use.
Robert PEJCHAL, Caitlin STEIN, Julia McCREARY
Filed: 8 Jun 20
Utility
Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use
3 Jan 23
Anti-CD3 binding domains and antibodies comprising them, including multispecific antibodies, with, inter alia, desirable T-cell activation and (re)directed target cell killing potency and developability, profiles are provided, as well as methods for their identification, isolation, and generation, and methods for their preparation and use.
Laura M. Walker, Robert Pejchal, Eric Krauland, Maximiliano Vasquez, Monica Wai Ling Leung
Filed: 8 May 18
Utility
FC Variants with Reduced Effector Function
15 Dec 22
The present invention provides Fc variants and polypeptides, e.g., antibodies and Fc fusion proteins, comprising such Fc variants.
Robert Pejchal, Eric Krauland, Maximiliano Vasquez, Michael Brown, Anthony Cooper
Filed: 24 Jun 22
Utility
Engineered Ph-dependent ANTI-CD3 Antibodies, and Methods for Their Generation and Use
1 Dec 22
Engineered pH-dependent anti-CD3 binding domains and antibodies and/or antigen-binding domains comprising same, including multispecific antibodies, with, inter alia, desirable T-cell activation and (re)directed target cell killing potency and developability, profiles are provided, as well as methods for their identification, isolation, and generation, and methods for their preparation and use.
James GEOGHEGAN, Bianka PRINZ, Robert PEJCHAL
Filed: 8 Jun 20
Utility
Anti-coagulation factor XI antibodies
29 Nov 22
Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz
Filed: 1 May 20
Utility
Anti-coagulation factor XI antibodies
1 Nov 22
Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz
Filed: 1 May 20
Utility
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
1 Nov 22
Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as methods for their identification, isolation, generation, and methods for their preparation and use are provided.
Laura M. Walker
Filed: 20 Oct 17
Utility
Anti-coagulation factor XI antibodies
25 Oct 22
Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz
Filed: 1 May 20
Utility
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
25 Oct 22
Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as nucleic acid sequences encoding such antibodies, methods for their identification, isolation, generation, and methods for their preparation and use are provided.
Laura M. Walker
Filed: 20 Oct 17